Tech Company Financing Transactions

Allink Biotherapeutics Funding Round

Allink Biotherapeutics, operating out of Shanghai, secured $42 million in funding from C&D Emerging Investment, Gaorong Capital and Legend Capital.

Transaction Overview

Announced On
11/29/2024
Transaction Type
Venture Equity
Amount
$42,000,000
Round
Series A
Proceeds Purpose
The company intends to use the funds to advance: Global clinical development of lead candidates ALK201 and ALK202 through Phase 1 studies in Australia, the United States and China; Enrichment of current portfolio by developing multiple highly competitive new assets in oncology and immunology; Further development of its proprietary bispecific antibody and ADC technology platform; Global footprint expansion.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2nd Floor, South Building, No. 2966, Jinke Road, Pudong New
Shanghai, Undisclosed
China
Phone
Undisclosed
Email Address
Not Recorded
Overview
Shanghai Allink Biotherapeutics Co., Ltd. established in 2023, is a pioneering biotechnology company specializing in bispecific antibody and antibody-drug conjugates (ADCs). The company's experienced R&D focuses on the discovery and clinical development of a diverse of FIC/BIC therapeutics.
Profile
Allink Biotherapeutics LinkedIn Company Profile
Social Media
Allink Biotherapeutics Company Twitter Account
Company News
Allink Biotherapeutics News
Facebook
Allink Biotherapeutics on Facebook
YouTube
Allink Biotherapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Hui Feng
  Hui Feng LinkedIn Profile  Hui Feng Twitter Account  Hui Feng News  Hui Feng on Facebook
Chief Operating Officer
Kehua Emba
  Kehua Emba LinkedIn Profile  Kehua Emba Twitter Account  Kehua Emba News  Kehua Emba on Facebook
VP - R & D
Li Li
  Li Li LinkedIn Profile  Li Li Twitter Account  Li Li News  Li Li on Facebook
VP - R & D
Xiaolin Wang
  Xiaolin Wang LinkedIn Profile  Xiaolin Wang Twitter Account  Xiaolin Wang News  Xiaolin Wang on Facebook


 

 

Browse more venture capital transactions:

Prev: 11/29/2024: Zenno Astronautics venture capital transaction
Next: 11/29/2024: Pathway Genomics venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary